Purinomia Biotech specializes in the development of biologicals and small molecules that specifically target ectonucleotidases, enzymes implicated in various diseases. This approach aims to enhance therapeutic efficacy by modulating nucleotide signaling pathways, addressing unmet medical needs in disease treatment.
Funding
$10.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ectonucleotidases, enzymes that modulate nucleotide signaling pathways, are implicated in various diseases, presenting a target for therapeutic intervention. Current treatments may not fully address the role of these enzymes in disease progression, leaving unmet medical needs.
Solution
Purinomia Biotech develops biologicals and small molecules designed to selectively target ectonucleotidases. By modulating nucleotide signaling pathways through targeted enzyme inhibition or activation, Purinomia aims to enhance therapeutic efficacy in disease treatment. Their approach focuses on developing novel therapeutics that address the specific role of ectonucleotidases in disease pathology, potentially leading to more effective treatments. This targeted modulation of nucleotide signaling offers a refined approach to managing diseases influenced by ectonucleotidase activity.
Target Audience
Purinomia Biotech's primary target audience includes pharmaceutical companies, research institutions, and clinical investigators focused on developing and studying novel therapies for diseases influenced by nucleotide signaling.
Features
- Development of biological therapeutics targeting specific ectonucleotidases.
- Creation of small molecule inhibitors designed to modulate ectonucleotidase activity.
- Focus on nucleotide signaling pathways as key therapeutic targets.
- Preclinical research investigating the efficacy of ectonucleotidase-modulating compounds in disease models.